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Tuberculosis (TB) is a contagious, infectious disease, due to Myco-
bacterium tuberculosis (MT) that has always been a permanent 
challenge over the course of human history, because of its severe 
social implications. It has been hypothesized that the genus Myco-
bacterium originated more than 150 million years ago. In the Mid-
dle Ages, scrofula, a disease affecting cervical lymph nodes, was 
described as a new clinical form of TB. The illness was known in 
England and France as “king’s evil”, and it was widely believed 
that persons affected could heal after a royal touch. In 1720, for the 
first time, the infectious origin of TB was conjectured by the Eng-
lish physician Benjamin Marten, while the first successful remedy 
against TB was the introduction of the sanatorium cure. The famous 
scientist Robert Koch was able to isolate the tubercle bacillus and 
presented this extraordinary result to the society of Physiology in 
Berlin on 24 March 1882. In the decades following this discovery, 
the Pirquet and Mantoux tuberculin skin tests, Albert Calmette and 
Camille Guérin BCG vaccine, Selman Waksman streptomycin and 
other anti-tuberculous drugs were developed.
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Summary
Introduction 
Tuberculosis (TB) is a contagious, infectious disease, due 
to Mycobacterium tuberculosis (MT), which usually lasts 
throughout the life course and determines the formation of 
tubercles in different parts of the body [1]. MT has very an-
cient origins: it has survived over 70,000 years and it cur-
rently infects nearly 2 billion people worldwide  [2]; with 
around 10.4 million new cases of TB each year, almost one 
third of the world’s population are carriers of the TB bacillus 
and are at risk for developing active disease [3].
TB has always been associated with a high mortality rate 
over the centuries, and also nowadays, it is estimated 
to be responsible for 1.4 million TB deaths, among in-
fectious diseases after human immunodeficiency virus 
(HIV) [3].
Due to its infectious nature, complex immunological re-
sponse, chronic progression and the need for long-term 
treatment, TB has always been a major health burden; in 
more recent years, the appearance of multi-drug resis-
tant forms and the current TB-HIV epidemic, associated 
with its severe social implications, treating and prevent-
ing TB have represented a permanent challenge over the 
course of human history [4, 5].
Ancient times: the first historical records
It has been hypothesized that the genus Mycobacterium 
originated more than 150 million years ago. Mycobac-
terium ulcerans, causing infections since ancient times, 
requires specific environmental conditions as reflected 
nowadays in its distribution worldwide [6].
Three million years ago, an early progenitor of MT 
might have infected early hominids in East Africa  [7] 
and 20.000-15.000 years ago, for the first time, the com-
mon ancestor of modern strains of MT might have ap-
peared [8, 9].
Egyptian mummies, dating back to 2400 BC, reveal 
skeletal deformities typical of tuberculosis; characteris-
tic Pott’s lesions are reported and similar abnormalities 
are clearly illustrated in early Egyptian art [10, 11].
Nevertheless, no evidence about TB lesions is reported 
in Egyptian papyri. The first written documents describ-
ing TB, dating back to 3300 and 2300 years ago, were 
found in India and in China respectively [12, 13].
Other written documents connected to TB are related to 
the Hebraism. The ancient Hebrew word schachepheth 
is used in the Biblical books of Deuteronomy and Leviti-
cus in order to describe TB [14]; in the same period, in 
the Andean region, archeological evidence of early TB, 
including Pott’s deformities, was provided by Peruvian 
mummies, suggesting that the disease was present even 
before the colonization of the first European pioneers in 
South America [15-18].
In the Ancient Greece TB was well known and called 
Phtisis. Hippocrates described Phtisis as a fatal dis-
ease especially for young adults, accurately defining its 
symptoms and the characteristic tubercular lung lesions.
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Excellent discoveries of the early scientists who studied 
TB were made in the same period: in Greece, Isocrates 
was the first author supposing that TB was an infectious 
disease, while Aristotle suggested the contagious nature 
of “king’s evil” in pigs and oxes [19].
In Roman times, TB is mentioned by Celso, Aretaeus of 
Cappadocia and Caelius Aurelianus, but it is not recognized 
as sharing the same etiology of extrapulmonary manifesta-
tions such as scrofula, Pott’s disease and TB lupus.
According to the Greek Clarissimus Galen, who became 
personal physician of the Roman Emperor Marcus Au-
relius in 174 AD, the symptoms of TB include fever, 
sweating, coughing and blood stained sputum; he rec-
ommended fresh air, milk and sea voyages as successful 
treatments for the disease [20-22]. 
After the decline of the Roman Empire, TB was wide-
spread in Europe in the VIII and XIX centuries, as wit-
nessed by several archaeological findings [23].
The Byzantine doctors Aetius of Amida, Alexander of 
Tralles and Paul of Aegina described the pulmonary and 
glandular forms of TB [24], while in the Arabic Empire, 
Avicenna supposed the contagious nature of TB.
Middle Ages and Renaissance time:  
the “king’s evil” and the discovery  
of extra pulmonary TB
In the Middle Ages, scrofula, a disease affecting cervi-
cal lymph nodes, was described as a new clinical form 
of TB. The illness was known in England and France as 
“king’s evil”, and it was widely believed that persons af-
fected could heal after a royal touch [25].
In the 12th century, William of Malmesbury reported 
complementary treatments including visits at royal 
tombs, the kings’ touch or the use of a coin-talisman.
The practice of the king’s touch established by English 
and French kings continued for several years. Queen 
Anne was the last English monarch to use this practice 
(1712), George I put an end to it in 1714, while in France 
it continued up to 1825 [26].
In the Middle Ages, moreover, the French surgeon Guy 
de Chauliac (1363) for the first time proposed a healing 
intervention for the cure of the “king’s evil” [27].
Guy de Chauliac was also strongly in favour of the re-
moval of scrofulous gland with an engraving, as recom-
mended by Paul of Aegina, who advised the surgical 
removal of the diseased gland, taking care not to harm 
vessels or nerves of which the neck region is rich [28].
As far as concerns the contagious nature of TB, a clear 
definition was first given by Girolamo Fracastoro in the 
sixteenth century [29].
The exact pathological and anatomical description of the 
disease was illustrated in 1679 by Francis Sylvius, in his 
work Opera Medica, in which he describes tubercles, 
their progression to abscesses, cavities and empyema in 
the lungs and in other sites of consumptive patients [30].
Short afterwards, in Italian health law, in particular in an 
edict issued by the Republic of Lucca in 1699, there is 
the first official reference to the infectious nature of the 
disease  [31]. In 1735 the Health Board of the Republic 
ordered the compulsory notification and isolation of con-
sumptives, forbidding their admission in public hospitals, 
and establishing specific places for their treatment [29].
XVIII-XIX centuries: the infectious theory 
and the isolation of the Koch bacillus 
In 1720, for the first time, the infectious origin of TB was 
conjectured by the English physician Benjamin Marten, 
in his publication “A new theory of Consumption”. For 
the early eighteenth century, Marten’s writings display a 
great degree of epidemiological insight [32].
Both terms consumption and phthisis were used in the 17th 
and 18th centuries, until in the mid-19th century Johann Lu-
kas Schönlein coined the term “tuberculosis” [33].
In the 18th century in Western Europe, TB had become 
epidemic with a mortality rate as high as 900 deaths 
per 100,000 inhabitants per year, more elevated among 
young people. For this reason, TB was also called “the 
robber of youth”.
During the industrial revolution, the diffusion of particu-
larly problematic social conditions, such as extremely de-
prived work settings, poorly ventilated and overcrowded 
housing, primitive sanitation, malnutrition and other risk 
factors, were intimately associated with the disease [26].
In 1838-39, up to a third of English tradesmen and em-
ployees died of TB, whereas the same proportion de-
creased to a sixth in the upper class [34].
The extreme anemic pallor of people affected by TB was 
at the origin of the new term “white plague”, coined dur-
ing the 18th century [20, 35].
One hundred years later, TB was defined as “Captain of 
All These Men of Death” because of its epidemic pro-
portions in Europe and North America, determining one 
in four deaths.
At the beginning of the 19th century, there was a large 
scientific debate about different theories concerning the 
etiopathological origin of phthisis, arguing whether it 
might be considered: an infectious disease – as generally 
considered in Southern Europe – an hereditary one – as 
stated in Northern Europe – or a form of cancer. On the 
other hand, the discussion was about scrofula, tubercles, 
and phthisis as separate disease entities or manifesta-
tions of the same illness [26].
In 1793, the caseous necrosis, “cheese-like”, phthisic 
abscesses were named “tubercles” by the Scottish pa-
thologist Matthew Baille [36].
In 1810, the French physician Gaspard-Laurent Bayle of 
Vernet described the disseminated “miliary” TB in his 
work Recerches sur la phthisie pulmonaire, recognizing 
TB not only as a disease affecting the lung, but a gen-
eralized one, clinically defined by coughing, difficulty 
in breathing, fever and purulent expectoration [37, 38].
In 1819, the French Theophile Laennac identified the 
presence of consolidation, pleurisy and pulmonary cavi-
tation as pathognomonic signs of pulmonary or extra-
pulmonary TB  [33]. Mycobacterium tuberculosis most 
commonly affects the respiratory tract, but it could also 
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infect gastrointestinal, bones, joints, nervous systems, 
lymph nodes, genitourinary tract and skin with inflam-
matory infiltration, caseation, necrosis, abscesses, fibro-
sis, formation of tubercles and calcification [39, 40].
He recognized tubercles as the characteristic signs of the 
first phase of phthisis. He described their first appear-
ance in the lungs, in their “miliary” (“millet seed-like”) 
form, their progressing to larger tubercles containing 
“cheese-like” (“caseous”) material, their breakdown into 
pus, and eventually forming cavities and empyema.
Extra-pulmonary phthisic tubercles were recognized 
in the intestines, liver, meninges and other organs, as 
also described by Sir Percivall Pott, a British surgeon 
that in 1779 defined as “Pott’s disease” the vertebral 
collapse and spinal cord paralysis caused by TB infec-
tion [33, 36, 37, 41, 42].
In 1843, the German physician Philipp Friedrich Hermann 
Klencke succeeded in the experimental reproduction of 
human and bovine forms of TB, causing generalized TB 
in rabbits, through a successful inoculation of material 
from a miliary tubercle into their liver and lungs [27].
In 1849 Lebert, publishing his work Traite Pratique des 
Maladies Scrofuleuses et Tuberculeuses, suggested that 
the “King’s evil” was a childhood disease that might 
cause suppuration and ulceration of different body’s 
sites such as skin, ears, eyes, joints, bones, with a differ-
ent pathogenesis from TB [43].
The first successful remedy against TB was the introduc-
tion of the sanatorium cure, described for the first time 
in 1854 in the doctoral dissertation “Tuberculosis is a 
curable disease” by Hermann Brehmer, a botany student 
suffering himself from TB, who reported his healing af-
ter a travel to the Himalayan Mountains [44].
Afterwards Brehmer founded an institution in Gorbers-
dorf, a mountain town situated in a fir forest, in order to 
cure patients with continuous fresh air and good nutrition.
The subsequent sanatoria were built with the same setup 
and permitted to cure a lot of TB patients in the next 
decades [45].
The infectious nature of TB was demonstrated in 1865 
by Jean-Antoine Villemin, a French military surgeon at 
the Army Medical School.
He formulated his hypothesis observing that TB was 
more frequent among soldiers who stationed for long 
times in barracks than among those in the field.
He also highlighted how healthy army recruits coming 
from the countryside often became consumptive some 
months after the beginning of their service.
Villemin’s experiments consisted in inoculating a rabbit with 
“a small amount of purulent liquid from a tuberculous cav-
ity” removed at autopsy from an individual died of TB [20].
As described in Villemin’s work Cause et nature de la 
tuberculose: son inoculation de l’homme au lapin, the 
inoculated animal remained alive and no disease signs 
were discovered, but at autopsy, three months later, ex-
tensive TB was evident [46].
Villemin suggested that phthisis could be similar to glan-
ders, an infectious disease in horses [20, 34, 36, 37, 47].
The infectious theory was well documented in Villemin’s 
work Études sur la tuberculose. Preuves rationelles et 
expérimentales de sa spécificité et de son inoculabilité, 
dated 1868 [48], in which he stated the presence of TB-
like illnesses in different animals [49].
The author also noticed that more crowded urban areas 
had a higher prevalence of TB and that some parts of the 
world, like New Zealand and Australia, seemed to have 
not known TB until the arrival of pioneers. 
Some years later, in 1867, Theodor Albrecht Ed-
win Klebs was one of the early scientists to try to iso-
late the TB bacillus, sowing tuberculous material on egg 
white, stored in sterile flasks.
In his experiments, the culture was quickly muddy and 
it was possible to recognize mobile bacilli, which, after 
inoculation into the peritoneal cavity, caused the disease 
in Guinea pigs [50].
The famous scientist Robert Koch was able to isolate 
the tubercle bacillus. Using the methylene blue staining 
recommended by Paul Ehrlich, he identified, isolated 
and cultivated the bacillus in animal serum. Finally he 
reproduced the disease by inoculating the bacillus into 
laboratory animals [51].
Robert Koch presented this extraordinary result to the 
Society of Physiology in Berlin on 24 March 1882, de-
termining a milestone in the fight against TB [52].
In the decades following this discovery, the Pirquet and 
Mantoux tuberculin skin tests, Albert Calmette and Ca-
mille Guérin (BCG) vaccine, Selman Waksman strepto-
mycin and other anti-tuberculous drugs were developed.
Koch contributed also to the elucidation of the infec-
tious etiology of TB and for his scientific results, he was 
awarded the Nobel prize in Medicine in 1905 [33, 51].
Nowadays TB is still a major public health problem, for 
this reason a combined strategy, based on improving 
drug treatment, diagnostic instruments, and prevention 
strategy, is necessary, in order to eradicate M. Tuberculo-
sis by the year 2050, as committed by the World Health 
Organization (WHO) [53].
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